The MOXIe Study

A study of omaveloxolone (RTA 408) in Friedreich's ataxia

MOXIe is a double blind, placebo-controlled, multi-center Phase 2 study of the safety and efficacy of omaveloxolone (RTA 408) in Friedreich's ataxia

About the Study

- Treatment: Omaveloxolone or placebo capsules taken by mouth once daily
- Approximately 8 visits over 16 weeks
- Primary endpoint: Change in peak workload, measured on a recumbent bicycle
- Cost of travel may be reimbursed

Criteria for Participation

- Between ages 16 and 40
- Genetically confirmed Friedreich's ataxia
- Willing to discontinue taking some medications
- Not pregnant, planning a pregnancy, or breastfeeding

Recruiting Study Center Locations



- Los Angeles, California: UCLA
  Susan Perlman, MD
- Gainesville, Florida: University of Florida
  S.H. Subramony, MD
- Tampa, Florida: University of South Florida
  Theresa Zesiewicz, MD
- Atlanta, Georgia: Emory University Hospital
  George Wilmot, MD
- Columbus, Ohio: Ohio State University
  Chad Hoyle, MD
- Philadelphia, Pennsylvania: CHOP
  David Lynch, MD
- Innsbruck, Austria: Medical University Innsbruck
  Sylvia Boesch, MD
- Parkville, Victoria, Australia: Murdoch Children's Research Institute
  Martin Delatycki, MD

MOXIe a study in Friedreich's ataxia

Contact information for participating study centers can be found on the clinicaltrials.gov listing

REATA PHARMACEUTICALS

Go to www.clinicaltrials.gov/ct2/show/NCT02255435 for more information

Version 1; September 2016